论文部分内容阅读
目的 探讨丙戊酸钠 (VPA)和卡马西平 (CBZ)治疗小儿癫痫的成本 -效果。方法 以随机对照临床试验VPA组 (4 3例 )和CBZ组 (4 2例 )作为分析模型 ,以上海市三级甲等医院的收费标准进行成本 -效果分析。结果 VPA治疗癫痫平均每减少一次发作的费用为 135 5 3元 ,较CBZ节约 6 1 14元 ;每控制 1例患儿的费用为92 1 82元 ,较CBZ节约 2 38 0 3元。在全部的费用中直接医疗费用占了较大部分。结论 同时考虑临床疗效和医疗费用 ,VPA治疗较CBZ有更好的成本 -效果。对于单一用药治疗小儿癫痫时 ,该结果值得临床借鉴。
Objective To investigate the cost-effectiveness of valproate (VPA) and carbamazepine (CBZ) in the treatment of epilepsy in children. Methods A randomized controlled clinical trial of VPA group (43 cases) and CBZ group (42 cases) were used as the analysis model, and the cost-effectiveness analysis was carried out in Shanghai Grade Three First Class Hospital. Results The average cost per episode of VPA for treatment of epilepsy was 135 5 3 yuan, which was 6 1 14 yuan lower than that of CBZ. The cost of one control for each child was 92 1 82 yuan, which was 2 383 yuan less than that of CBZ. Direct medical costs account for a large part of the total costs. Conclusions While considering both clinical and medical costs, VPA has a better cost-effectiveness than CBZ. For single-drug treatment of pediatric epilepsy, the results deserve clinical reference.